Highlight
This study identifies two distinct anti-müllerian hormone (AMH) decline trajectories leading to the final menstrual period, differentiated by initial AMH levels and rate of decline. Unexpectedly, a lower baseline AMH with slower decline trajectory correlates with adverse postmenopausal cardiovascular risk profiles despite fewer vasomotor symptoms.
Study Background
Specialty calculators
For clinical reference; use professional judgment.
